Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Clinical trial NCT05552937 · RECRUITING
Trial details
- NCT number
- NCT05552937
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-06
- Primary completion
- 2025-04-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.